Combination treatment with flavonoid morin and telomerase inhibitor MST-312 reduces cancer stem cell traits by targeting STAT3 and telomerase
Open Access
- 31 May 2016
- journal article
- research article
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 49 (2), 487-498
- https://doi.org/10.3892/ijo.2016.3546
Abstract
Colorectal cancer (CRC) is one of the most commonly diagnosed cancers worldwide. The malignant CRC that undergoes metastasis in the advanced stage is usually refractory to existing chemotherapy and shows a poor prognosis. However, to date, efficient targeted-therapy for metastatic CRC is ill-defined. We tested the hypothesis that combined treatment of flavonoid morin and telomerase inhibitor MST‑312 may reduce the cancer stem cell (CSC) traits. To characterize CSC phenotype, we performed the CD133/CD44 subpopulation profiling, tumorsphere formation assay, cell invasion assay and wound healing assay. We have examined the augmenting effects of the combined treatment of morin and MST‑312 for 5-FU (5-fluorouracil) efficacy in human colorectal cancer. Morin and MST‑312 combined treatment reduced CD133 (+) and CD44 (+) subpopulations in human colorectal and breast cancer cells, respectively. Tumorsphere formation and cell invasiveness were decreased with the morin and MST‑312 combination treatment. Consistent with these data, morin and MST‑312 treatment decreased the wound healing capacity of human breast cancer cells. Stress and apoptosis antibody arrays revealed that there were specific upregulated and downregulated proteins resulting from different treatments. Phosphorylation levels of BAD, p53 and Chk1 were enhanced upon morin/MST‑312 treatments in HT-29 cells, whereas caspase-3 cleavage level and expression of IκBα were downregulated by combined morin/MST‑312 treatment in SW620 cells. Finally, morin and MST‑312 co-treatment further augmented the 5-FU efficacy, chemosensitizing the 5-FU resistant human colorectal cancer cells. Taken together, our study suggests that novel targeted-therapy can be implemented by using flavonoid morin and telomerase inhibitor MST‑312 for improved cancer prognosis.Keywords
This publication has 36 references indexed in Scilit:
- Telomerase reverse transcriptase promotes epithelial–mesenchymal transition and stem cell-like traits in cancer cellsOncogene, 2012
- STAT3 mediates resistance of CD44+CD24-/low breast cancer stem cells to tamoxifen in vitroJournal of Biomedical Research, 2012
- Targeting Signal Transducer and Activator of Transcription 3 Pathway by Cucurbitacin I Diminishes Self-Renewing and Radiochemoresistant Abilities in Thyroid Cancer-Derived CD133+ CellsThe Journal of pharmacology and experimental therapeutics, 2012
- Stat3 Mediates Expression of Autotaxin in Breast CancerPLOS ONE, 2011
- Inhibition of telomerase activity preferentially targets aldehyde dehydrogenase-positive cancer stem-like cells in lung cancerMolecular Cancer, 2011
- 5-Fluorouracil response in a large panel of colorectal cancer cell lines is associated with mismatch repair deficiencyBritish Journal of Cancer, 2010
- Expression of activated signal transducer and activator of transcription-3 predicts poor prognosis in cervical squamous-cell carcinomaBritish Journal of Cancer, 2009
- Effect of morin on tissue lipid peroxidation and antioxidant status in 1, 2-dimethylhydrazine induced experimental colon carcinogenesisInvestigational New Drugs, 2008
- Morin (3,5,7,2′,4′-Pentahydroxyflavone) Abolishes Nuclear Factor-κB Activation Induced by Various Carcinogens and Inflammatory Stimuli, Leading to Suppression of Nuclear Factor-κB–Regulated Gene Expression and Up-regulation of ApoptosisClinical Cancer Research, 2007
- Cancer Stem Cells—Perspectives on Current Status and Future Directions: AACR Workshop on Cancer Stem CellsCancer Research, 2006